Marker Therapeutics (NASDAQ:MRKR) Posts Earnings Results, Beats Estimates By $0.02 EPS

Marker Therapeutics (NASDAQ:MRKR) announced its quarterly earnings data on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02, FiscalAI reports. The company had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.68 million. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%.

Marker Therapeutics Price Performance

Shares of NASDAQ:MRKR traded down $0.04 during mid-day trading on Friday, reaching $1.42. 28,062 shares of the company traded hands, compared to its average volume of 74,933. The company’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.43. The firm has a market cap of $23.67 million, a PE ratio of -1.67 and a beta of 1.43. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Marker Therapeutics during the 2nd quarter valued at approximately $33,000. Virtu Financial LLC purchased a new stake in Marker Therapeutics during the 3rd quarter valued at approximately $25,000. Two Sigma Investments LP purchased a new stake in Marker Therapeutics during the 3rd quarter valued at approximately $33,000. XTX Topco Ltd grew its holdings in Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Marker Therapeutics by 41.7% during the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after buying an additional 24,500 shares in the last quarter. 22.39% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.